Skip to main
GOVX
GOVX logo

Geovax Labs (GOVX) Stock Forecast & Price Target

Geovax Labs (GOVX) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Geovax Labs Inc. is positioned for growth due to its distressed valuation coupled with a promising product pipeline that includes a next-generation COVID-19 vaccine, GEO-CM04S1, which exhibits robust safety and durability signals. The company is also actively engaged in developing innovative vaccines and therapies for various infectious diseases and solid tumors, indicating strong research and development momentum. Additionally, the management's efforts to enhance liquidity and monitor sector M&A dynamics further underscore a strategic approach that could potentially unlock value for investors.

Bears say

Geovax Labs Inc is currently facing challenges as their key clinical program, GEO-CM04S1, although meeting interim immune-response targets, is juxtaposed against the halted mRNA comparator arm in a critical chronic lymphocytic leukemia (CLL) study that failed to achieve benchmarks. This development raises concerns about the overall viability and competitive positioning of Geovax's product pipeline in a crowded biotechnology market. Furthermore, the company's reliance on the successful completion of its clinical trials, amid setbacks in related studies, suggests a heightened risk profile that may adversely impact investor confidence and stock performance.

Geovax Labs (GOVX) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Geovax Labs and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Geovax Labs (GOVX) Forecast

Analysts have given Geovax Labs (GOVX) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Geovax Labs (GOVX) has a Strong Buy consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Geovax Labs (GOVX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.